Baltimore Ends Opioid Lawsuit After Major Loss on Appeal, Forfeiting $152 Million Verdict

Baltimore's ambitious legal campaign against pharmaceutical distributors ended quietly this week as city officials filed court documents dismissing the remainder of their lawsuit against McKesson and Cencora (formerly AmerisourceBergen). The decision follows a devastating ruling by Maryland's highest court that rejected the legal theory underpinning the city's case, wiping out a $152 million jury verdict and potentially limiting how other jurisdictions pursue opioid litigation.

The dismissal marks the conclusion of a high-stakes legal strategy that set Baltimore apart from most local governments. While states and municipalities across the country accepted settlement offers from opioid manufacturers and distributors, Baltimore pressed forward with a jury trial, securing what initially appeared to be a landmark victory. In late 2024, city residents serving on the jury awarded $266 million after hearing seven weeks of testimony about how the companies allegedly failed to halt suspiciously large orders of prescription painkillers.

From Jury Verdict to Legal Defeat

The path from that courtroom triumph to Friday's dismissal reveals the precarious nature of public nuisance litigation against regulated industries. Baltimore City Circuit Judge Lawrence Fletcher-Hill had already reduced the jury's award to $152 million, presenting the city with a choice: accept the reduced amount or risk a new trial. The city's legal team took the money while simultaneously appealing to the Maryland Supreme Court, hoping to preserve the full verdict.

The drug companies appealed as well, and last month the state's highest court delivered a unanimous rebuke to Baltimore's legal theory. The justices ruled that public nuisance law could not encompass complex social problems like the opioid crisis, particularly given the extensive federal and state regulatory framework already governing prescription drug distribution.

"After conferring with our counsel, Baltimore made the difficult decision to dismiss the lawsuit against the remaining defendants," said Jonas Poggi, spokesperson for Mayor Brandon Scott, in a statement acknowledging the legal dead end. "Unfortunately, the Supreme Court of Maryland's recent rulings leave us no path forward to hold these defendants liable in the courts for their egregious conduct in causing and continuing the opioids crisis in our city."

The Public Nuisance Precedent

The Maryland Supreme Court's rejection of the public nuisance theory carries implications extending far beyond Baltimore's case. The legal doctrine, which traditionally addressed interference with public rights like clean air or navigable waters, has become a favored tool for cities and states seeking to hold corporations accountable for widespread social harms. The opioid crisis, climate change, and gun violence have all spawned public nuisance lawsuits in recent years.

Maryland's highest court determined that applying public nuisance law to the opioid epidemic would stretch the doctrine beyond recognition. The justices emphasized that prescription opioids are legal products subject to comprehensive regulation by the Food and Drug Administration, the Drug Enforcement Administration, and state pharmacy boards. Unlike classic public nuisance cases involving unregulated pollution or obstruction of public roadways, opioid distribution occurs within a framework of licensing requirements, tracking systems, and prescribing protocols.

This reasoning aligns with decisions from other state supreme courts that have similarly limited public nuisance claims against opioid companies. However, some jurisdictions have reached opposite conclusions, creating a patchwork of precedents that complicates national litigation strategy. The split among state courts may eventually invite review by the U.S. Supreme Court, though no certiorari petition is currently pending.

What Baltimore Keeps—and Loses

Despite the dismissal, Baltimore retains more than $400 million secured through settlements with other opioid defendants, including Johnson & Johnson, reached before the trial against McKesson and Cencora. Those earlier agreements, negotiated during the same period when the city was preparing its courtroom showdown, represent a substantial recovery for a municipality that has experienced the highest overdose death rate of any major American city.

The $400 million figure approaches the amount Maryland will receive as part of the $26 billion national settlement with major opioid companies—a striking comparison that illustrates both the potential rewards and risks of Baltimore's go-it-alone approach. By refusing to join the global settlement, the city secured comparable compensation from some defendants while gambling on a larger payout from others. That gamble ultimately failed when the Maryland Supreme Court intervened.

What Baltimore loses extends beyond the $152 million verdict. The dismissal eliminates the possibility of appellate precedent affirming that pharmaceutical distributors can be held liable for downstream consequences of their distribution practices. Such precedent would have strengthened the hand of other jurisdictions still pursuing litigation and potentially deterred future corporate conduct. Instead, Maryland law now contains authoritative language limiting public nuisance claims against regulated industries.

The City's Ongoing Crisis

Baltimore's legal defeat arrives even as the city continues grappling with an overdose epidemic that has claimed thousands of lives over the past two decades. While national overdose deaths have declined approximately 19 percent since their August 2023 peak, Baltimore's mortality rate remains stratospheric. The city recorded over 1,000 overdose deaths annually during the worst years of the crisis, with fentanyl driving the majority of fatalities.

The $400 million in secured settlements provides resources for addressing this ongoing emergency, though converting dollars into outcomes has proven challenging nationwide. Baltimore has established an Opioid Restitution Fund to channel settlement money into treatment, prevention, and harm reduction programs. City officials have emphasized equity in distribution, targeting neighborhoods with the highest overdose rates for expanded services.

Whether those investments can meaningfully reduce mortality remains uncertain. Settlement funds arrive over 15-18 years, creating sustainability challenges for programs launched with initial payments. Workforce shortages in addiction medicine complicate treatment expansion. And the evolving drug supply—now featuring medetomidine and other synthetic substances that resist standard overdose reversal—requires adaptive responses that outpace traditional public health planning.

Implications for National Litigation

The Maryland Supreme Court's ruling contributes to a growing body of case law that will shape opioid litigation for years to come. While the $50 billion in national settlements resolved the majority of claims against major manufacturers and distributors, thousands of individual cases remain pending in state and federal courts. Those cases increasingly turn on legal theories rather than factual disputes, as discovery has established extensive records of corporate conduct.

Baltimore's experience illustrates the risks of pressing novel legal theories to final judgment. The city's attorneys bet that a jury of Baltimore residents, witnessing daily the devastation of the opioid crisis, would deliver both a substantial verdict and a vindication of the public nuisance approach. They were half right—the jury responded sympathetically, but appellate courts proved less receptive.

For other jurisdictions considering similar strategies, the lesson involves careful assessment of state-specific nuisance law and appellate precedent. Some states have broader public nuisance doctrines that might accommodate opioid claims; others have already foreclosed such theories. The variation means that identical factual patterns can produce diametrically opposite legal outcomes depending on venue.

Looking Forward

Baltimore's dismissal filing closes one chapter in the city's response to the opioid crisis while opening questions about alternative accountability mechanisms. With litigation against major distributors now foreclosed, attention may shift to regulatory advocacy, legislative reform, or targeting different defendants within the pharmaceutical supply chain.

The city has already demonstrated willingness to pursue aggressive legal strategies, suggesting that Friday's dismissal may not represent the end of Baltimore's courtroom involvement with the opioid industry. Pharmacy chains, individual prescribers, and newer defendants in the synthetic opioid supply chain remain potential targets. Each would require different legal theories, but Baltimore's experience has provided valuable intelligence about what approaches survive appellate scrutiny.

For the broader addiction treatment field, the dismissal serves as a reminder that legal accountability and public health progress operate on different timelines. Even successful litigation delivers resources years after the harms occurred, and appellate reversals can eliminate those resources entirely. Sustainable progress likely depends less on courtroom victories than on sustained investment in treatment infrastructure, harm reduction services, and addressing the social determinants that make communities vulnerable to addiction in the first place.

Baltimore will continue receiving settlement payments from earlier agreements, and those funds will support expanded services. But the $152 million that vanished with Friday's filing represents treatment slots never created, recovery housing never built, and prevention programs never launched—the tangible losses that follow when legal theories fail.